Aravive, Inc.
ARAV
|
$0.0401
4.74%
4M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-97.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-85.6% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 2,949,862
http://www.aravive.com
Sec Filling | Patents | 17 employees
(US) Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.
cancer t-cell ovarian cancer treatment ceiling
add to watch list Paper trade email alert is off
Press-releases
Carisma Therapeutics Announces Changes to its Board of Directors
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.47%
H: 0.23%
C: -0.99%
CRIS | $14.96 -6.21% -6.62% 20K
|
Health Technology
|
| O: 0.7%
H: 16.87%
C: 16.87%
therapeutics
Aravive, Inc. to Delist from The Nasdaq Stock Market
Published: 2024-01-17 (Crawled : 21:00) - globenewswire.com
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: -55.58%
H: 32.65%
C: 21.43%
nasdaq market
Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments
Published: 2023-08-14 (Crawled : 17:00) - biospace.com/
VRPX | $3.87 11.53% 10.34% 20K
|
|
| O: -6.82%
H: 9.76%
C: 9.76%
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: -1.61%
H: 0.91%
C: -5.3%
virpax pharmaceuticals results
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
Published: 2023-08-02 (Crawled : 20:00) - globenewswire.com
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: -62.35%
H: 0.0%
C: -39.63%
cancer results study
Urothelial Carcinoma Market is Expected to Showcase a Significant Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - MedPacto, AstraZeneca, EMD Serono, Bayer, Merck, Bristol-Myers Squibb, Inovio, Seagen, Incyte
Published: 2023-07-31 (Crawled : 09:00) - prnewswire.com
TYRA | $14.68 1.59% 1.57% 190K
|
Health Technology
|
| O: -0.42%
H: 8.05%
C: 3.71%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 0.34%
H: 1.07%
C: -1.81%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: 0.0%
URGN | $14.32 0.56% 0.56% 320K
|
Health Technology
|
| O: -1.59%
H: 0.94%
C: -2.65%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 3.56%
H: 0.0%
C: 0.0%
NKTR | $1.3 -3.7% -3.85% 3.6M
|
Health Technology
|
| O: -0.73%
H: 4.99%
C: -0.96%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.03%
H: 1.4%
C: 1.03%
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: 6.38%
H: 0.33%
C: -6.67%
ADXS | $0.6455 12.48% 2.3K
|
Health Technology
|
| O: -1.71%
H: 3.48%
C: -5.43%
companies expected growth market
Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023
Published: 2023-07-28 (Crawled : 11:00) - globenewswire.com
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: -0.75%
H: 10.53%
C: 6.02%
renal cancer pancreatic trials
Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023
Published: 2023-07-14 (Crawled : 11:00) - globenewswire.com
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: -5.29%
success biotech commercial
Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)
Published: 2023-06-13 (Crawled : 20:00) - globenewswire.com
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: 1.23%
H: 1.22%
C: -3.66%
nasdaq grant
Aravive To Participate in the Jefferies Global Healthcare Conference
Published: 2023-06-05 (Crawled : 20:00) - globenewswire.com
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: -2.25%
H: 4.6%
C: 1.72%
conference global
Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023
Published: 2023-05-25 (Crawled : 21:00) - globenewswire.com
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: 6.12%
H: 3.21%
C: 1.28%
renal asco cell trial
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10